Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI

Clinical trial NCT02593539 · COMPLETED

Trial details

NCT number: NCT02593539
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Activated PI3K-delta Syndrome

Start date: 2016-07-22
Primary completion: 2020-06-04
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.